Juliet Escalon
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Immunotherapy and Immune Responses, Monoclonal and Polyclonal Antibodies Research, Protein Degradation and Inhibitors, Cancer Treatment and Pharmacology
Most-Cited Works
- → Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming(2007)295 cited
- → Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma(2015)91 cited
- → A Phase II Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma(2015)16 cited
- → Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab (JNJ-64407564) for the Treatment of Relapsed and/or Refractory Multiple Myeloma(2021)15 cited
- → Hair depigmentation as an indicator of durable response to CTLA-4 therapy.(2010)13 cited
- → Extramedullary Relapse Post CAR-T(2022)9 cited
- → Outcomes and Management of Red Blood Cell Transfusions in Multiple Myeloma Patients Treated with Daratumumab(2015)8 cited
- → Comparison of the immunogenicity of Montanide ISA 51 adjuvant and cytokine-matured dendritic cells in a randomized controlled clinical trial of melanoma vaccines(2009)8 cited
- → Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study(2008)8 cited
- → A phase II study of panobinostat with lenalidomide and weekly dexamethasone in myeloma.(2015)7 cited